Intellia 治療公司
US ˙ NasdaqGM ˙ US45826J1051

SecurityNTLA / Intellia Therapeutics, Inc.
InstitutionD.a. Davidson & Co.
Latest Disclosed Ownership93,260 shares
Latest Disclosed Value $ 1,195,593
D.a. Davidson & Co. reports 11.02% increase in ownership of NTLA / Intellia Therapeutics, Inc.

On May 5, 2026 - D.a. Davidson & Co. filed a 13F-HR form disclosing ownership of 93,260 shares of Intellia Therapeutics, Inc. (US:NTLA) valued at $1,195,593 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 29, 2026 disclosing 84,000 shares of Intellia Therapeutics, Inc.. This represents a change in shares of 11.02% during the quarter. The current value of the position is $1,375,585 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-05 2026-03-31 13F INTELLIA THERAPEUTICS COM 45826J105 93,260 9,260 11.02 1,196 58.28 0.0072
2026-01-29 2025-12-31 13F INTELLIA THERAPEUTICS COM 45826J105 84,000 19,780 30.80 755 -31.92 0.0046
2025-10-22 2025-09-30 13F INTELLIA THERAPEUTICS COM 45826J105 64,220 10,100 18.66 1,109 118.74 0.0071
2025-07-30 2025-06-30 13F INTELLIA THERAPEUTICS COM 45826J105 54,120 28,100 107.99 508 174.05 0.0036
2025-04-28 2025-03-31 13F INTELLIA THERAPEUTICS COM 45826J105 26,020 11,250 76.17 185 7.56 0.0015
2025-01-31 2024-12-31 13F INTELLIA THERAPEUTICS COM 45826J105 14,770 -1,480 -9.11 172 -48.35 0.0014
2024-11-13 2024-09-30 13F INTELLIA THERAPEUTICS COM 45826J105 16,250 4,150 34.30 334 23.33 0.0028
2024-08-01 2024-06-30 13F INTELLIA THERAPEUTICS COM 45826J105 12,100 12,100 271 0.0024
2019-01-29 2018-12-31 13F INTELLIA THERAPEUTICS COM 45826J105 0 -10,166 -100.00 0 -100.00
2018-11-13 2018-09-30 13F INTELLIA THERAPEUTICS COM 45826J105 10,166 -8,729 -46.20 291 -43.71 0.0052
2018-08-02 2018-06-30 13F INTELLIA THERAPEUTICS COM 45826J105 18,895 -324 -1.69 517 27.65 0.0101
2018-05-04 2018-03-31 13F INTELLIA THERAPEUTICS COM 45826J105 19,219 2,395 14.24 405 25.39 0.0084
2018-02-08 2017-12-31 13F INTELLIA THERAPEUTICS COM 45826J105 16,824 16,824 323 0.0068
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.